|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$21,000
|
N/A
|
National Institutes of Health
|
|
Training Program in Cancer Biology
|
5T32CA078207-19
|
$554,252
|
|
AARONSON, STUART
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
|
5R01CA201247-03
|
$511,614
|
|
ABDEL-WAHAB, OMAR
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
WalkIT: Neighborhood walkability and moderation of adaptive walking interventions
|
5R01CA198915-04
|
$568,727
|
|
ADAMS, MARC
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$83,611
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,352,827
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Genetic identification of novel mTORC1 regulators and homeostatic signaling mechanisms
|
1F31CA228241-01
|
$44,524
|
|
ADELMANN, CHARLES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Probing the role of the IRE1alpha-XBP1 pathway in normal and malignant hematopoiesis
|
5K22CA218467-02
|
$192,575
|
|
ADORO, STANLEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
New Roles for the WTX Tumor Suppressor and Endocytosis in WNT signaling
|
1F31CA228289-01
|
$34,190
|
|
AGAJANIAN, MEGAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mutagenesis and migration in glioblastoma cells
|
1R21CA220111-01A1
|
$179,240
|
|
AHN, EUN HYUN
|
UNIVERSITY OF WASHINGTON
|
|
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform
|
5U24CA210950-03
|
$279,908
|
|
AKBANI, REHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
MULTIMODAL PRECLINICAL CANCER IMAGING AND THERAPY RESEARCH SPECIALIST
|
5R50CA211481-04
|
$170,003
|
|
AKERS, WALTER
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cancer Prevention and Control Health Disparities Training Program
|
5T32CA078447-18
|
$161,530
|
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
A collaborative structural hub to promote Cancer Center science and drug design
|
5R50CA211440-03
|
$145,562
|
|
ALESHIN, ALEXANDER
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Modulation of wild type and mutant p53 by HMGA1
|
1F32CA221010-01A1
|
$58,654
|
|
ALEXANDER, KATHERINE
|
UNIVERSITY OF PENNSYLVANIA
|
|
p63 as a novel factor promoting pregnancy-induced HER2-positive breast cancer
|
5K22CA190653-03
|
$157,743
|
|
ALEXANDROVA, EVGUENIA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
5F30CA220847-02
|
$49,524
|
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
|
Profiling signaling activity and gene expression in single, pancreatic adenocarcinoma cells using CE-RNA-Seq
|
1R01CA224763-01A1
|
$575,272
|
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-05
|
$575,397
|
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Cancer Related Health Disparities Training Program
|
5T32CA163184-08
|
$266,221
|
|
ALLEN, MICHELE
|
UNIVERSITY OF MINNESOTA
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-04
|
$362,569
|
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-09
|
$1,222,825
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Tumor Plasticity
|
5R35CA220446-02
|
$1,140,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
5R01CA198015-04
|
$366,000
|
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
In vivo regulators of TERT promoter mutant glioblastoma
|
1F32CA228365-01
|
$58,654
|
|
AMEN, ALEXANDRA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
Coordinating Center: Molecular and Cellular Findings of Screen-Detected Lesions
|
5U01CA196386-05
|
$895,779
|
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bitter Melon Component and Colon Cancer Prevention
|
5R01CA190291-05
|
$544,710
|
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-05
|
$701,988
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)
|
5UG1CA189863-06
|
$2,840,966
|
|
ANDERSON, DANIEL
|
HEALTHPARTNERS INSTITUTE
|
|
Performance, safety, and efficacy of a new cyrotherapy device for cervical dyspla
|
5UH3CA189923-05
|
$762,683
|
|
ANDERSON, JEAN
|
JOHNS HOPKINS UNIVERSITY
|
|
RIP140 as a mediator of Estrogen Receptor action in tumor associated macrophages
|
5F31CA220978-02
|
$35,725
|
|
ANDREANO, KAITLYN
|
DUKE UNIVERSITY
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
|
5R01CA201124-03
|
$259,646
|
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Values-based Intervention to Increase Endocrine Therapy Adherence among Breast Cancer Survivors
|
1R21CA218723-01A1
|
$207,450
|
|
ARCH, JOANNA
|
UNIVERSITY OF COLORADO
|
|
Research Training in Pediatric Oncology
|
5T32CA136432-10
|
$491,462
|
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
Total relevant funding to Wilm's Tumor for this search: $6,014,517
|